Aduro Biotech, Inc. (NASDAQ:ADRO) released its earnings results on Tuesday. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03), Briefing.com reports. The company had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. Aduro Biotech’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.54) earnings per share.
Shares of Aduro Biotech (ADRO) traded down 4.088% during trading on Wednesday, hitting $7.625. 885,831 shares of the stock were exchanged. The company’s market cap is $568.92 million. Aduro Biotech has a 1-year low of $6.01 and a 1-year high of $15.53. The firm’s 50-day moving average is $10.07 and its 200 day moving average is $10.84.
In other news, COO Gregory W. Schafer sold 40,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $12.17, for a total value of $486,800.00. Following the completion of the sale, the chief operating officer now owns 133,879 shares of the company’s stock, valued at $1,629,307.43. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas W. Dubensky sold 50,000 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $11.38, for a total transaction of $569,000.00. Following the completion of the sale, the insider now directly owns 80,812 shares of the company’s stock, valued at approximately $919,640.56. The disclosure for this sale can be found here. In the last three months, insiders sold 342,745 shares of company stock valued at $3,956,397. 6.60% of the stock is currently owned by company insiders.
Several equities analysts recently commented on ADRO shares. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. BidaskClub cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company started coverage on shares of Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Aduro Biotech presently has an average rating of “Buy” and a consensus price target of $19.14.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
What are top analysts saying about Aduro Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro Biotech Inc. and related companies.